Extended long‐term efficacy and safety of velmanase alfa treatment up to 12 years in patients with alpha‐mannosidosis
Journal of Inherited Metabolic Disease · 2025-01 · 48 (1)
DOI: 10.1002/jimd.12799 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 09.10.2024. Verfasst von Nathalie Guffon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Reference Center for Inherited Metabolic Disorders, Femme Mère Enfant Hospital, Hospices Civils de Lyon, Lyon, France. Hauptthemen laut MEDLINE: Enzyme Replacement Therapy, alpha-Mannosidosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chiesi Farmaceutici S.p.A., Chiesi Farmaceutici.
Abstract (Originalsprache)
Enzyme replacement therapy (ERT) using velmanase alfa previously showed promising efficacy and safety outcomes for up to 4 years of therapy in patients with alpha‐mannosidosis. This pooled analysis from two multicenter, open‐label phase IIIb extension trials rhLAMAN‐07 ( N = 13; NCT01908712) and rhLAMAN‐09 ( N = 8; NCT01908725) evaluated the long‐term effects of velmanase alfa. Sixteen patients who previously completed phase I–III rhLAMAN‐02/‐03/‐04/‐05/‐08 trials and five ERT‐naïve patients were enrolled. Patients received 1 mg/kg velmanase alfa once weekly. Endpoints included changes from treatment baseline (before initial dose of velmanase alfa in any trial) in serum oligosaccharides, 6‐minute walk test (6MWT), 3‐minute stair climb test (3MSCT), pulmonary function (forced vital capacity [FVC], % predicted), serum immunoglobulin G (IgG) levels, and adverse events. The overall cohort comprised 21 patients, divided by age at treatment baseline into pediatric ( n = 14) and adult subgroups ( n = 7). Distance walked according to 6MWT increased or stabilized in pediatric patients, while in adults either stabilization or slight decline was observed. Similarly, pediatric patients performed better in the 3MSCT. Changes in FVC, % predicted, were comparable in both subgroups up to ~6 years of observation, diverging thereafter. Overall, sustained serum oligosaccharide clearance and serum IgG level increase was observed upon treatment initiation and persisted until last common observation. Velmanase alfa treatment was generally well tolerated, with the majority of reported adverse events being of mild‐to‐moderate intensity. With follow‐up of up to 12 years, long‐term efficacy and safety outcomes indicate continued benefits of velmanase alfa in patients with alpha‐mannosidosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Reference Center for Inherited Metabolic Disorders, Femme Mère Enfant Hospital, Hospices Civils de Lyon, Lyon, France.
- Center for Inherited Metabolic Diseases, Departments of Pediatrics and Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Center for Genomic Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Pediatrics, Nutrition and Metabolic Diseases, The Children's Memorial Health Institute, Warsaw, Poland.
- Chiesi Farmaceutici S.p.A., Parma, Italy.
ORCID-Profile: Nathalie Guffon
Förderung
- Chiesi Farmaceutici S.p.A.
- Chiesi Farmaceutici
Zitieren
APA
Guffon, N., Borgwardt, L., Tylki-Szymańska, A., Ballabeni, A., Donà, F., Joseph, A., Nienhuis, H., Maugeri, C., & Lund, A. (2025). Extended long‐term efficacy and safety of velmanase alfa treatment up to 12 years in patients with alpha‐mannosidosis. Journal of Inherited Metabolic Disease, 48(1). https://doi.org/10.1002/jimd.12799
Vancouver
Guffon N, Borgwardt L, Tylki-Szymańska A, Ballabeni A, Donà F, Joseph A, et al. Extended long‐term efficacy and safety of velmanase alfa treatment up to 12 years in patients with alpha‐mannosidosis. Journal of Inherited Metabolic Disease. 2025;48(1). doi:10.1002/jimd.12799
BibTeX
@article{Guffon2025,
author = {Guffon, Nathalie and Borgwardt, Line and Tylki-Szymańska, Anna and Ballabeni, Andrea and Donà, Francesca and Joseph, Amer and Nienhuis, Henriët and Maugeri, Caterina and Lund, Allan},
title = {Extended long‐term efficacy and safety of velmanase alfa treatment up to 12 years in patients with alpha‐mannosidosis},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
volume = {48},
number = {1},
doi = {10.1002/jimd.12799}
}
EUVIMED